Abstract
Specific blocking of interactions between ligands and receptors along the angiogenic pathways represents an effective approach for enhancing the efficacy as well as reducing adverse effects of chemotherapy. Over the past decade, there was a rapid progression in the application of this therapeutic strategy in cancer treatment. Anti-angiogenic therapy is the most promising targeted therapy for ovarian cancer. The addition of bevacizumab to conventional chemotherapy, either in the first-line setting or at disease relapse, may improve overall survival (OS) of ovarian cancer patients, at least in a subset of patients with poor prognosis. In this article, we summarize published data on the major agents used for anti-angiogenic therapy in ovarian cancers. We will review the molecular mechanisms, results of clinical trial of existing agents and describe the development of new agents. The limitations and side effects of angiogenesis inhibitor are also discussed.
Keywords: Ovarian cancer, molecular targeting, anti-angiogenic agents, angiogenesis, cancer therapy, inhibitor.
Current Drug Targets
Title:Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors
Volume: 18 Issue: 10
Author(s): Ping Duan, Lili Fan, Quansheng Gao, Bal Mukunda Silwal, Mulan Ren, Yang Shen*Wanglei Qu*
Affiliation:
- Department of Obstetrics and Gynecology, Zhongda Hospital, Southeast University, Nanjing 210009,China
- Department of Obstetrics and Gynecology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325027,China
Keywords: Ovarian cancer, molecular targeting, anti-angiogenic agents, angiogenesis, cancer therapy, inhibitor.
Abstract: Specific blocking of interactions between ligands and receptors along the angiogenic pathways represents an effective approach for enhancing the efficacy as well as reducing adverse effects of chemotherapy. Over the past decade, there was a rapid progression in the application of this therapeutic strategy in cancer treatment. Anti-angiogenic therapy is the most promising targeted therapy for ovarian cancer. The addition of bevacizumab to conventional chemotherapy, either in the first-line setting or at disease relapse, may improve overall survival (OS) of ovarian cancer patients, at least in a subset of patients with poor prognosis. In this article, we summarize published data on the major agents used for anti-angiogenic therapy in ovarian cancers. We will review the molecular mechanisms, results of clinical trial of existing agents and describe the development of new agents. The limitations and side effects of angiogenesis inhibitor are also discussed.
Export Options
About this article
Cite this article as:
Duan Ping, Fan Lili, Gao Quansheng, Silwal Mukunda Bal, Ren Mulan, Shen Yang*, Qu Wanglei*, Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors, Current Drug Targets 2017; 18 (10) . https://dx.doi.org/10.2174/1389450118666170329095807
DOI https://dx.doi.org/10.2174/1389450118666170329095807 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development of Multifunctional Nanoparticles for Targeted Drug Delivery and Noninvasive Imaging of Therapeutic Effect
Current Drug Discovery Technologies Applications of 211At and 223Ra in Targeted Alpha-Particle Radiotherapy
Current Radiopharmaceuticals Gadolinium Oxide Nanoparticles Enhance the Cytotoxicity of Chemotherapeutic Drugs by Blocking Autophagic Flux in Human Ovarian Cancer Cells
Current Nanoscience Towards Tyrosine Metabolism in Esophageal Squamous Cell Carcinoma
Combinatorial Chemistry & High Throughput Screening SPECT-CT and PET-CT in Oncology - An Overview
Current Medical Imaging Epidermal Growth Factor Receptor as a Target for Anti-Cancer Agent Design
Anti-Cancer Agents in Medicinal Chemistry Pharmacogenetics of Phase I and Phase II Drug Metabolism
Current Pharmaceutical Design High Throughput Study for Molecular Mechanism of Metformin Pre-Diabetic Protection <i>via</i> Microarray Approach
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Approaches to Cancer Therapy Using Oncolytic Viruses
Current Molecular Medicine Overexpression of Nemo-like Kinase Promotes the Proliferation and Invasion of Lung Cancer Cells and Indicates Poor Prognosis
Current Cancer Drug Targets Novel Polymer-Ceramics for Bone Repair and Regeneration
Recent Patents on Biomedical Engineering (Discontinued) A Fresh Prospect of Extracellular Matrix Hydrolytic Enzymes and Their Substrates
Current Pharmaceutical Design Anti-Inflammatory Drugs and Prediction of New Structures by Comparative Analysis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Integrins: Regulators of Tissue Function and Cancer Progression
Current Pharmaceutical Design Cellular Targets and Mechanisms in the Cytotoxic Action of Non-biodegradable Engineered Nanoparticles
Current Drug Metabolism TRAIL as Biomarker and Potential Therapeutic Tool for Cardiovascular Diseases
Current Drug Targets Identification of Drug Candidates for Breast Cancer Therapy Through Scaffold Repurposing: A Brief Review
Current Drug Research Reviews Fibroblast Activation Protein in Remodeling Tissues
Current Molecular Medicine Protein Arrays: Recent Achievements and their Application to Study the Human Proteome
Current Proteomics Oleamide Derivatives are Prototypical Anti-Metastasis Drugs that Act by Inhibiting Connexin 26
Current Drug Safety